Elmiron Maculopathy Secondary to Pentosan Polysulfate (PPS) Toxicity: Medical...
New Elmiron Study Suggests Established Maculopathy Patients Should be Asked About Possible Elmiron Use (Posted by Tom Lamb at Drug Injury Watch) Elmiron maculopathy secondary to pentosan polysulfate...
View ArticleBeovu Side Effects Have Caused Eye Doctors to Avoid Beovu and Use Other...
In Addition, the Three New Beovu Lawsuits Filed for Patients with Vision Loss May Further Impact Novartis Market Share (Posted by Tom Lamb at Drug Injury Watch) Since being approved by the FDA in 2019,...
View ArticleXeljanz FDA Drug Safety Communication in February 2021 Puts Heightened...
Apparently, the Xeljanz Black Box Warning Added in July 2019 Was Not Enough; Is a Xeljanz Recall Coming Next? (Posted by Tom Lamb at Drug Injury Watch) In early February 2021 the FDA doubled-down on...
View ArticleXeljanz Has A New Drug Safety Issue, We Just Don't Know How Significant It...
February 2021 FDA Warning: Xeljanz Increased Risks for Serious Heart-related Problems and Cancers (Posted by Tom Lamb at Drug Injury Watch) During the past few years, there have been some Xeljanz drug...
View ArticlePast Elmiron Use Linked to Pigmentary Maculopathy and Vision Loss, Again, by...
Patients with High Levels of Elmiron Use Have More Than a 2-Times Increased Risk of Developing Serious Eye Problems (Posted by Tom Lamb at Drug Injury Watch) Two new medical journal articles provide...
View ArticleBeovu Vision Loss Lawsuits Involve Serious Eye Problems due to Beovu...
People Need to Know These Beovu Lawsuits are Individual Cases; No Beovu Class Actions for Beovu Eye Problems (Posted by Tom Lamb at Drug Injury Watch) Starting in January 2021 Beovu lawsuits have been...
View ArticleElmiron Drug Safety-related Labeling Changes for Pigmentary Maculopathy Side...
March 2021: New Elmiron Medication Guide for Patients Points Out Retinal Pigmentary Eye Problems (Posted by Tom Lamb at Drug Injury Watch) By means of a March 12, 2021, Supplemental Approval letter for...
View ArticlePossible Ramifications of Recent FDA Alert About Xeljanz Heart Problems and...
Do the JAK Inhibitors Rinvoq and Olumiant Also Have an Increased Risk of These Adverse Drug Events and Side Effects? (Posted by Tom Lamb at Drug Injury Watch) In February 2021 this FDA Drug Safety...
View ArticleBelviq Recall Aftermath: Further FDA Action in 2021 Means There Will Be No...
Belviq Was Withdrawn From Market Due to Increased Risk of Certain Cancers: Pancreatic, Colon, Rectal, And Lung (Posted by Tom Lamb at Drug Injury Watch) Recently we found some further FDA action...
View ArticleXeljanz and Other JAK Inhibitors: Drug Safety Concerns Indicated by Recent...
Possible FDA Advisory Committee Meeting for Xeljanz, Olumiant, and Rinvoq Mentioned by Commentators (Posted by Tom Lamb at Drug Injury Watch) Drug safety observers are watching the effects a recent FDA...
View ArticleFirst Monotherapy Ocrevus PML Case Report: Patient Used Ocrevus for 2 Years...
Compare 9 Earlier Cases of PML in MS Patients After Ocrevus Treatments: Those Involved Previous Tysabri and/or Gilenya Use (Posted by Tom Lamb at Drug Injury Watch) Pharmaceutical company Genentech...
View ArticleDrug-induced Liver Injury: Guidelines for Diagnosing and Managing Patients...
American College of Gastroenterology Requested a Group of Experts to Develop New Guidelines for DILI (Posted by Tom Lamb at Drug Injury Watch) This medical journal article, "ACG Clinical Guideline:...
View ArticleLong-term Use of Interstitial Cystitis Treatment Drug Elmiron Linked to...
We Take a 2021 Look at the Findings on Increased Risk of Elmiron-associated Pigmentary Maculopathy (Posted by Tom Lamb at Drug Injury Watch) At the 2021 Southeastern Educational Congress of Optometry...
View ArticleFDA Safety Evaluation Finds Ocaliva-related Liver Injury in Primary Biliary...
May 2021 FDA Drug Safety Communication: Ocaliva Label Change: Prescribing Information Will be Adding and Updating Warnings (Posted by Tom Lamb at Drug Injury Watch) Ocaliva (obeticholic acid) was...
View ArticleBeovu Vision Loss Side Effects Continue to Plague Novartis, Ending 3 Key...
And Novartis "has yet to identify the root cause behind Beovu’s safety problem", According to a News Report (Posted by Tom Lamb at Drug Injury Watch) Starting back in February 2020, when the American...
View ArticleTasigna Drug Injury Lawsuits Consolidated for Pretrial Proceedings: June 2021...
New Jersey Tasigna Multi-county Litigation (MCL), Federal Court Tasigna Multidistrict Litigation (MDL) (Posted by Tom Lamb at Drug Injury Watch) In early June 2021, the New Jersey Supreme Court...
View ArticleProducts Recall: Philips Bi-Level PAP, CPAP, and Mechanical Ventilator...
For Patients with Polyester-based Polyurethane (PE-PUR) Exposures, Potential Health Risks Include Cancers and Organ Failures (Posted by Tom Lamb at Drug Injury Watch) In June 2021, the healthcare...
View ArticlePossible FDA Advisory Committee Meeting for Xeljanz, Rinvoq, and Other Janus...
Outside Experts Could Review All JAK Inhibitors Risk/Benefit Profiles as Regards Several Requested New Indications (Posted by Tom Lamb at Drug Injury Watch) A few months ago we wrote about a possible...
View ArticleInvokana, Farxiga, Jardiance, Other SGLT2 Inhibitors Associated With Retinal...
Increased Risk for This New Vision/Eyes Side Effect Highest in Elderly Patients and Chronic Kidney Disease Patients (Posted by Tom Lamb at Drug Injury Watch) In June 2021 it was reported that Invokana,...
View ArticleSome Current Drug Injury Lawsuits Being Filed Against Pharmaceutical...
Drug Injury Lawsuits are Personal Injury or Wrongful Death Cases Involving a Serious Side Effect or a Severe Adverse Reaction (Posted by Tom Lamb at Drug Injury Watch) A drug injury lawsuit usually...
View Article
